Skip to main content
. 2020 Sep 23;14(2):431–442. doi: 10.1038/s41385-020-00344-9

Fig. 5. CCR2 blockade reduces moDC and T cell recruitment to the lungs of pIgR−/− mice.

Fig. 5

a Flow cytometry plots demonstrating the effectiveness of the CCR2 antagonist RS-504393 in reducing lung moDCs in aged (20–22 months) pIgR−/− mice. b Quantification of DC subsets (as % of CD11c+MHCIIhi cells) in the lungs of aged pIgR−/− mice with and without CCR2 antagonist. c, e Representative flow cytometry plots showing CD4+ and CD8+ T lymphocytes in aged (20–22 months) pIgR−/− mice with and without CCR2 antagonist treatment. d, f Quantification of CD4+ and CD8+ T lymphocytes shown in (c, e). b, d *p < 0.01 compared to sham-treated pIgR−/− mice (t-test); n = 4–6 mice/group. f *p < 0.05 compared to sham-treated pIgR−/− mice (t-test); n = 4–6 mice/group. Box-and-whisker plots represent median, interquartile range, and range.